MedTrace Logo

Comparison of Repetitive Magnetic Stimulation and Exercise on Quadriceps Function in COPD

NCT00737698 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2023-09-28

Study results available
· View outcomes & findings →

Summary

Background Chronic Obstructive Pulmonary Disease (COPD) patients develop leg weakness and a reduced walking capacity, due to reduced leg muscle oxygen-utilising capacity (OUC). Animal experiments indicate that low muscle levels of Peroxisome Proliferator-Activated Receptors (PPAR) cause the reduced muscle OUC.

Aims

In COPD patients, investigate whether:

1. reduced muscle PPAR levels cause reduced leg muscle OUC, by investigating a correlation between these in muscle samples (Study 1).
2. training increases muscle PPAR levels in proportion to increases in OUC, as should occur if PPARs control OUC (Study 2).
3. muscle PPAR levels and walking capacity correlate (Study 1 and 2).

3\. the new technique of repetitive stimulation of the nerve to the leg with a magnet (rMS) improves muscle OUC (Study 2).

Study 1 Leg weakness and walking ability are assessed in 75 patients, then a leg muscle sample is taken to measure PPARs and OUC.

Study 2 60 Study 1 patients have either cardiovascular training, rMS, or no training, for 8 weeks, then are re-studied as in Study 1.

Importance If reduced PPAR levels correspond with leg weakness, medicines can be developed to target these receptors and treat weakness. If rMS is effective, it can be offered to patients.

Conditions

Interventions

OTHER

Exercise

Physiotherapist-supervised exercise course (endurance and resistance exercises) for 2 hours twice a week for 8 weeks

OTHER

Repetitive magnetic stimulation

Repetitive magnetic stimulation of the intramuscular branches of the femoral nerve for 3 hours twice a week for 8 weeks

Sponsors & Collaborators

  • Wellcome Trust

    collaborator OTHER

  • Maastricht University

    collaborator OTHER

  • Magstim Company, Whitland, Wales

    collaborator UNKNOWN

  • Imperial College London

    lead OTHER

Principal Investigators

  • Michael I Polkey, MBBSFRCPPhD · Royal Brompton Hospital/Imperial College

  • Samantha A Sathyapala, MABMBChPhD · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-10-31
Completion
2010-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00737698 on ClinicalTrials.gov